Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02978144 · ClinicalTrials.gov registry record · Phase 2

Lung Imaging of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 study, sponsored by Columbia University.

Terminated
Registry status
Phase 2
Development phase
34
Enrollment target

NCT02978144 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 34 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02978144, a Phase 2 study, was terminated before completion, sponsored by Columbia University.

TERMINATED
Registry status
Phase 2
Development phase
34 participants
Enrollment target

Study Summary

This is a prospective interventional study examining the use of Annexin - a radioactive tracer, in assessing lung damage in healthy volunteers, healthy volunteers actively smoking, and patients with moderate and severe chronic obstructive pulmonary disease (COPD). All study participants will undergo a CT scan, pulmonary testing, and blood test. The study procedures are done in one day. The aim of this study is to determine if Annexin can be used as a marker to detect lung injury early on and aid in the future diagnosis of COPD.

Interventions

  • DRUG AxV-128/Tc

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2017-06-15
Est. Completion 2019-10-08
Phase Phase 2

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT02978144

The ClinicalTrials.gov registry entry for NCT02978144 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which AxV-128/Tc is the first listed.

NCT02978144 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02978144 about?

NCT02978144 is a clinical study titled "Lung Imaging of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)". This is a prospective interventional study examining the use of Annexin - a radioactive tracer, in assessing lung damage in healthy volunteers, healthy volunteers actively smoking, and patients with moderate and severe chronic obstructive pulmonary disease (COPD). All study participants will undergo...

What is the current status of trial NCT02978144?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2017-06-15. Estimated completion is 2019-10-08.

What interventions are being tested in trial NCT02978144?

The interventions under investigation include: AxV-128/Tc (DRUG).

Who is sponsoring clinical trial NCT02978144?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.